Barbiturates, Serum or Plasma, Quantitative

2012201
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive

Ordering Recommendation

Optimize drug therapy and monitor patient adherence. Useful for ruling out barbiturate exposure. For follow-up testing of a presumptive result, Barbiturates, Urine Quantitative (2012213) is preferred.

Mnemonic

BARBS SP

Methodology

Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Tue, Thu, Sat

Reported

1-4 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 3.5 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

Reference Interval

Drugs Covered
 Cutoff Concentrations
Butalbital 50 ng/mL
Pentobarbital 50 ng/mL
Phenobarbital 50 ng/mL

Interpretive Data

Methodology: Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry.

Positive cutoff: 50 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/16/2021
X
X
X
X
N/A

CPT Codes

80345 (Alt code: G0480)

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2012202 Phenobarbital, S/P, Quant 3948-7
2012203 Butalbital, S/P, Quant 6895-7
2012204 Pentobarbital, S/P, Quant 3924-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Amobarbitone
  • Amytal
  • Axocet
  • Butalbital
  • Fioricet
  • Fiorinal
  • Luminal
  • Nembutal
  • Pain Management
  • Pentobarbital
  • Phenobarbital
  • Phenobarbitone
  • Quinalbartbitone
  • Sandoptal
  • Seconal
  • Solfoton
  • Tuinal
Barbiturates, Serum or Plasma, Quantitative